Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.

Capello CF, Bourke CH, Ritchie JC, Stowe ZN, Newport DJ, Nemeroff A, Owens MJ.

J Pharmacol Exp Ther. 2011 Oct;339(1):275-85. doi: 10.1124/jpet.111.183855. Epub 2011 Jul 20.

2.
3.

Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.

Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S.

Br J Pharmacol. 2005 Mar;144(5):695-702.

4.

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S.

Psychopharmacology (Berl). 2006 Oct;188(3):263-72. Epub 2006 Sep 6.

PMID:
16955282
5.

Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring.

Olivier JD, Vallès A, van Heesch F, Afrasiab-Middelman A, Roelofs JJ, Jonkers M, Peeters EJ, Korte-Bouws GA, Dederen JP, Kiliaan AJ, Martens GJ, Schubert D, Homberg JR.

Psychopharmacology (Berl). 2011 Oct;217(3):419-32. doi: 10.1007/s00213-011-2299-z. Epub 2011 Apr 14.

PMID:
21487650
6.

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.

Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S.

Psychopharmacology (Berl). 2007 Apr;191(2):333-9. Epub 2007 Jan 19.

PMID:
17235610
7.

Fluoxetine during pregnancy: impact on fetal development.

Morrison JL, Riggs KW, Rurak DW.

Reprod Fertil Dev. 2005;17(6):641-50. Review.

PMID:
16263070
8.

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S.

Am J Psychiatry. 2004 May;161(5):826-35.

PMID:
15121647
9.

Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations.

Bundgaard C, Sveigaard C, Brennum LT, Stensbøl TB.

Xenobiotica. 2012 Mar;42(3):256-65. doi: 10.3109/00498254.2011.618953. Epub 2011 Oct 21.

PMID:
22017605
10.

Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone.

Nagano M, Liu M, Inagaki H, Kawada T, Suzuki H.

Neuropharmacology. 2012 Aug;63(2):292-300. doi: 10.1016/j.neuropharm.2012.03.027. Epub 2012 Apr 13.

PMID:
22710353
11.

Neonatal exposure to citalopram selectively alters the expression of the serotonin transporter in the hippocampus: dose-dependent effects.

Weaver KJ, Paul IA, Lin RC, Simpson KL.

Anat Rec (Hoboken). 2010 Nov;293(11):1920-32. doi: 10.1002/ar.21245.

12.

Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.

Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM.

Mol Psychiatry. 2008 Jan;13(1):65-73. Epub 2007 May 22.

PMID:
17519929
13.

Movement disorders and neurochemical changes in zebrafish larvae after bath exposure to fluoxetine (PROZAC).

Airhart MJ, Lee DH, Wilson TD, Miller BE, Miller MN, Skalko RG.

Neurotoxicol Teratol. 2007 Nov-Dec;29(6):652-64. Epub 2007 Jul 19.

PMID:
17761399
14.

Perinatal vs genetic programming of serotonin states associated with anxiety.

Altieri SC, Yang H, O'Brien HJ, Redwine HM, Senturk D, Hensler JG, Andrews AM.

Neuropsychopharmacology. 2015 May;40(6):1456-70. doi: 10.1038/npp.2014.331. Epub 2014 Dec 19.

15.

Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities.

Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP.

PLoS One. 2008 Jul 23;3(7):e2782. doi: 10.1371/journal.pone.0002782. Erratum in: PLoS One. 2009;4(9). doi: 10.1371/annotation/71abed9d-9ee9-4be0-a663-0d469750e13a.

16.

Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex.

Geldof M, Freijer JI, van Beijsterveldt L, Langlois X, Danhof M.

Br J Pharmacol. 2008 Jul;154(6):1369-78. doi: 10.1038/bjp.2008.179. Epub 2008 May 19.

18.

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL.

JAMA. 2005 May 18;293(19):2372-83. Review.

PMID:
15900008
19.

Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).

National Toxicology Program..

Natl Toxicol Program Tech Rep Ser. 2008 Mar;(539):1-266.

20.

Effects of neonatal fluoxetine exposure on behavior across development in rats selectively bred for an infantile affective trait.

Zimmerberg B, Germeyan SC.

Dev Psychobiol. 2015 Mar;57(2):141-52. doi: 10.1002/dev.21264. Epub 2014 Dec 12.

PMID:
25503615

Supplemental Content

Support Center